Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

• US 6,284,725 B1
• Filed: 04/30/1999
• Issued: 09/04/2001
• Est. Priority Date: 10/08/1998
• Status: Expired due to Term

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Bionebraska, Inc.
• Inventors: Coolidge, Thomas R., Ehlers, Mario R. W.
• Primary Examiner(s): DAVENPORT, AVIS MICHELLE
• Application Number:
  US09/302,596
• Time in Patent Office: 858 Days
• Field of Search: 514/12, 514/2, 530/324, 424/185.1
• US Class Current: 424/433
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.

Claims

1. A method for amelioration of organ tissue injury caused by reperfusion of blood flow following a period of ischemia, which comprises:

administering to an individual in need of such treatment an effective amount of a composition which includes a compound which binds to a receptor for glucagon-like peptide-1, in a pharmaceutical carrier.

2. The method of claim 1 wherein the glucagon-like peptide-1 is GLP-1 or a biologically active analogue thereof.

3. The method of claim 1 wherein the pharmaceutical carrier is selected from the group consisting of saline, buffered saline, dextrose, water, glycerol, ethanol, lactose, phosphate, mannitol, arginine, treholose, and combinations thereof.

4. The method of claim 1 wherein the administering to an individual in need of treatment is at dose level of 0.1 pmol/kg/min. up to 10 pmol/kg/min.

5. The method of claim 4 wherein there is concurrent administration of glucose.

6. The method of claim 5 wherein there is concurrent administration of potassium.

7. The method of claim 4 wherein there is concurrent administration of a free radical scavenger.

8. The method of claim 1 wherein administration commences within 4 hours of an ischemic event.

9. The method of claim 8 wherein administration occurs within 4 hours of an ischemic event and continues thereafter.

10. The method of claim 1 wherein administration is intravenously.

11. The method of claim 1 wherein administration is by subcutaneous or micropressure injection, deep lung insufflation, external or implant pump, depot injection, and other sustained release mechanisms, oral delivery and patch, buccal and other cross skin and membrane mechanisms.

12. The method of claim 1 wherein the organ tissue is the myocardium.

13. The method of claim 8 wherein administration occurs as soon as possible after the event.